CL2023001418A1 - Inhibidor de integrina y usos de este. - Google Patents
Inhibidor de integrina y usos de este.Info
- Publication number
- CL2023001418A1 CL2023001418A1 CL2023001418A CL2023001418A CL2023001418A1 CL 2023001418 A1 CL2023001418 A1 CL 2023001418A1 CL 2023001418 A CL2023001418 A CL 2023001418A CL 2023001418 A CL2023001418 A CL 2023001418A CL 2023001418 A1 CL2023001418 A1 CL 2023001418A1
- Authority
- CL
- Chile
- Prior art keywords
- methods
- inhibitors
- integrin inhibitor
- crystalline forms
- integrin
- Prior art date
Links
- 229940125798 integrin inhibitor Drugs 0.000 title 1
- 239000003112 inhibitor Substances 0.000 abstract 3
- 102000006495 integrins Human genes 0.000 abstract 2
- 108010044426 integrins Proteins 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000013078 crystal Substances 0.000 abstract 1
- 238000000113 differential scanning calorimetry Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000002411 thermogravimetry Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
- C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
- C07C309/35—Naphthalene sulfonic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
En la presente descripción se proporcionan inhibidores de integrina, composiciones de estos, y métodos para su uso. Tambien se describen formas cristalinas de sales de los inhibidores, junto con métodos para preparar las formas cristalinas. Se proporcionan datos de difracción de polvo de rayos X, análisis termogravimétrico, y datos de calorimetría diferencial de barrido de las formas cristalinas. Los inhibidores de integrina son útiles en el tratamiento de, entre otras, las enfermedades fibróticas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063116042P | 2020-11-19 | 2020-11-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023001418A1 true CL2023001418A1 (es) | 2023-10-30 |
Family
ID=81709878
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023001418A CL2023001418A1 (es) | 2020-11-19 | 2023-05-17 | Inhibidor de integrina y usos de este. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US12018025B2 (es) |
| EP (1) | EP4247472A4 (es) |
| JP (1) | JP2023550428A (es) |
| KR (1) | KR20230121761A (es) |
| CN (1) | CN116710169A (es) |
| AU (1) | AU2021381516A1 (es) |
| CA (1) | CA3173755A1 (es) |
| CL (1) | CL2023001418A1 (es) |
| CO (1) | CO2023006522A2 (es) |
| CR (1) | CR20230262A (es) |
| CU (1) | CU20230026A7 (es) |
| DO (1) | DOP2023000101A (es) |
| EC (1) | ECSP23045278A (es) |
| IL (1) | IL302651A (es) |
| MX (1) | MX2023005889A (es) |
| PE (1) | PE20240114A1 (es) |
| TW (1) | TW202235417A (es) |
| WO (1) | WO2022109598A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018119087A1 (en) | 2016-12-23 | 2018-06-28 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| TWI841573B (zh) | 2018-06-27 | 2024-05-11 | 美商普萊恩醫療公司 | 具有未分支連接子之胺基酸化合物及使用方法 |
| TW202408530A (zh) * | 2022-07-09 | 2024-03-01 | 美商普萊恩醫療公司 | 整合素抑制劑及其與其他藥劑併用之用途 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015048819A1 (en) | 2013-09-30 | 2015-04-02 | The Regents Of The University Of California | Anti-alphavbeta1 integrin compounds and methods |
| AU2016228852A1 (en) | 2015-03-10 | 2017-10-19 | The Regents Of The University Of California | Anti-alphavbeta1 integrin inhibitors and methods of use |
| CN109996541A (zh) | 2016-09-07 | 2019-07-09 | 普利安特治疗公司 | N-酰基氨基酸化合物及其使用方法 |
| WO2018119087A1 (en) | 2016-12-23 | 2018-06-28 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| MA52117A (fr) | 2017-02-28 | 2022-04-06 | Morphic Therapeutic Inc | Inhibiteurs de l'intégrine (alpha-v) (bêta-6) |
| CA3054604A1 (en) | 2017-02-28 | 2018-09-07 | Morphic Therapeutic, Inc. | Inhibitors of .alpha.v.beta.6 integrin |
| DK3761980T3 (da) | 2018-03-07 | 2024-01-29 | Pliant Therapeutics Inc | Aminosyreforbindelser og fremgangsmåder til anvendelse |
| TWI841573B (zh) | 2018-06-27 | 2024-05-11 | 美商普萊恩醫療公司 | 具有未分支連接子之胺基酸化合物及使用方法 |
| US11521996B2 (en) * | 2018-07-20 | 2022-12-06 | Semiconductor Energy Laboratory Co., Ltd. | Imaging panel comprising a photoelectric conversion element and a first pixel circuit, and imaging device |
| EP3843728A4 (en) | 2018-08-29 | 2022-05-25 | Morphic Therapeutic, Inc. | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN |
| WO2020047239A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | INHIBITING αV β6 INTEGRIN |
| WO2020047208A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| TW202028179A (zh) | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
| WO2020139379A1 (en) * | 2018-12-28 | 2020-07-02 | LunaPBC | Community data aggregation, completion, correction, and use |
| EP3923857B8 (en) * | 2019-02-15 | 2024-04-17 | Clean Bite, LLC | Oral hygiene appliance |
| AU2020273158A1 (en) | 2019-04-08 | 2021-11-11 | Pliant Therapeutics, Inc. | Dosage forms and regimens for amino acid compounds |
| EP4146264A4 (en) * | 2020-05-07 | 2024-07-24 | Pliant Therapeutics Inc | TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS |
| TWI843503B (zh) * | 2020-06-03 | 2024-05-21 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| TW202233224A (zh) * | 2020-10-21 | 2022-09-01 | 美商寇峇有限公司 | 用組合療法治療纖維化之方法 |
| MX2023012794A (es) | 2021-04-30 | 2023-12-15 | Pliant Therapeutics Inc | Regímenes de dosificación expandidos para inhibidores de integrina. |
| US20240350494A1 (en) | 2021-09-03 | 2024-10-24 | Pliant Therapeutics, Inc. | Therapeutic modulation of integrins |
| KR20240102970A (ko) | 2021-10-14 | 2024-07-03 | 플라이언트 테라퓨틱스, 인크. | 인테그린 억제제 및 다른 작용제와 조합된 그의 용도 |
| WO2023225119A1 (en) | 2022-05-18 | 2023-11-23 | Pliant Therapeutics, Inc. | Stabilization of integrin inhibitors |
-
2021
- 2021-11-19 IL IL302651A patent/IL302651A/en unknown
- 2021-11-19 TW TW110143265A patent/TW202235417A/zh unknown
- 2021-11-19 WO PCT/US2021/072510 patent/WO2022109598A1/en active Application Filing
- 2021-11-19 PE PE2023001662A patent/PE20240114A1/es unknown
- 2021-11-19 MX MX2023005889A patent/MX2023005889A/es unknown
- 2021-11-19 KR KR1020237020570A patent/KR20230121761A/ko unknown
- 2021-11-19 JP JP2023530225A patent/JP2023550428A/ja active Pending
- 2021-11-19 CR CR20230262A patent/CR20230262A/es unknown
- 2021-11-19 EP EP21895890.8A patent/EP4247472A4/en active Pending
- 2021-11-19 CA CA3173755A patent/CA3173755A1/en active Pending
- 2021-11-19 AU AU2021381516A patent/AU2021381516A1/en active Pending
- 2021-11-19 US US17/531,074 patent/US12018025B2/en active Active
- 2021-11-19 CN CN202180090550.5A patent/CN116710169A/zh active Pending
- 2021-11-19 CU CU2023000026A patent/CU20230026A7/es unknown
-
2023
- 2023-05-17 CL CL2023001418A patent/CL2023001418A1/es unknown
- 2023-05-17 CO CONC2023/0006522A patent/CO2023006522A2/es unknown
- 2023-05-18 DO DO2023000101A patent/DOP2023000101A/es unknown
- 2023-06-16 EC ECSENADI202345278A patent/ECSP23045278A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DOP2023000101A (es) | 2023-09-29 |
| CA3173755A1 (en) | 2022-05-27 |
| PE20240114A1 (es) | 2024-01-22 |
| CU20230026A7 (es) | 2024-01-10 |
| EP4247472A1 (en) | 2023-09-27 |
| IL302651A (en) | 2023-07-01 |
| TW202235417A (zh) | 2022-09-16 |
| JP2023550428A (ja) | 2023-12-01 |
| EP4247472A4 (en) | 2024-10-09 |
| KR20230121761A (ko) | 2023-08-21 |
| CR20230262A (es) | 2023-07-26 |
| ECSP23045278A (es) | 2023-07-31 |
| WO2022109598A1 (en) | 2022-05-27 |
| CO2023006522A2 (es) | 2023-06-09 |
| MX2023005889A (es) | 2023-06-06 |
| US20220177468A1 (en) | 2022-06-09 |
| AU2021381516A9 (en) | 2024-10-24 |
| CN116710169A (zh) | 2023-09-05 |
| US12018025B2 (en) | 2024-06-25 |
| AU2021381516A1 (en) | 2023-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023001418A1 (es) | Inhibidor de integrina y usos de este. | |
| CL2019002777A1 (es) | Compuestos que inhiben la proteína mcl-1. | |
| ECSP109910A (es) | Derivados de n-(arilamino) sulfonamidas que incluyen polimorfos como inhibidores de mek así como composiciones, métodos de uso y de preparación de los mismos | |
| UY33491A (es) | ?Derivados de sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina?. | |
| UY36285A (es) | Compuestos que inhiben la proteína mcl-1 | |
| DOP2016000281A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
| CU20180152A7 (es) | Pirimidin-2-ilamino-1h-pirazoles útiles como inhibidores de lrrk2 | |
| UY32916A (es) | Nuevas pirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones | |
| CR20120591A (es) | Derivados de aminopirimidina como moduladores de la lrrk2 | |
| NI201800051A (es) | Compuestos de imidazo[4, 5-c]quinolin-2-ona y su uso en eltratamiento de cáncer | |
| UY33501A (es) | Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina | |
| CL2012002733A1 (es) | Compuestos derivados de ácido 1-amino-2-ciclopropiletilborónico, inhibidores de proteasoma; composición farmacéutica; uso en el tratamiento del cáncer; procedimiento de preparacion; compuestos intermediarios. | |
| CL2022000093A1 (es) | Imidazopirimidinas como inhibidores de eed y uso de estas | |
| CY1126141T1 (el) | Κρυσταλλικη μορφη του υδριτη ελευθερης βασης λορλατινιμπης | |
| UY35535A (es) | ?Derivados de fenil sulfonamidas?. | |
| ECSP16074478A (es) | Compuestos novedosos | |
| UY39517A (es) | Inhibidores de la btk | |
| NI201600176A (es) | Compuestos de 1, 3, 4 - tiadiazol y uso de los mismos para el tratamiento del cáncer. | |
| CL2021002110A1 (es) | Hidroxipiridoxazepinas como activadores de nrf2. | |
| ECSP19066134A (es) | COMPUESTOS DE TIPO IMIDAZO[4,5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CÁNCER | |
| UY38786A (es) | Agonistas de receptores tipo toll | |
| CR20190344A (es) | Activador de nrf2 | |
| CO2024013531A2 (es) | Formas sólidas, sales y procesos de preparación de un inhibidor de cdk2 | |
| ECSP22083772A (es) | Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso | |
| UY35536A (es) | ?derivados de sulfonamida?. |